Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
BNTC
BNTC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BNTC News
Benitec Reports Q2 Earnings Miss with Strategic Upgrade
4d ago
seekingalpha
Significant Progress in BB-301 Clinical Trials
4d ago
Newsfilter
Benitec Biopharma Announces Financial Results for Q2 2026 and Offers Operational Update
4d ago
moomoo
Benitec Biopharma Reports Q2 EPS of USD -0.26
4d ago
moomoo
Benitec Biopharma Reports Q2 Operating Loss of USD 13.4 Million
4d ago
moomoo
Benitec Biopharma Reports Q2 Net Loss of USD 11.8 Million
4d ago
moomoo
Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes
Jan 16 2026
NASDAQ.COM
Benitec Biopharma Reports Positive Long-Term Results for BB-301 in OPMD Treatment
Jan 11 2026
NASDAQ.COM
Benitec's BB-301 Therapy Shows Significant Improvement in Dysphagia
Jan 11 2026
Globenewswire
Wall Street Analysts Forecast an 87.48% Increase for Benitec Biopharma (BNTC): Key Insights to Consider
Dec 05 2025
NASDAQ.COM
Benitec Biopharma Inc. Reveals Pricing for $100 Million Common Stock Sale
Nov 06 2025
Newsfilter
HC Wainwright & Co. Reaffirms Buy Rating for Benitec Biopharma and Increases Price Target to $35
Nov 04 2025
Benzinga
Benitec Biopharma to Update on Phase 1b/2a Clinical Trial of BB-301 for Oculopharyngeal Muscular Dystrophy
Nov 03 2025
Yahoo Finance
Top Analysts Recommend 3 Stocks to Purchase Now, 9/24/2025
Sep 24 2025
TipRanks
Benitec Reports GAAP EPS of -$1.05, Exceeding Expectations by $0.72
Sep 23 2025
SeekingAlpha
Benitec Biopharma Announces Financial Results for Full Year 2025 and Offers Operational Update
Sep 22 2025
Newsfilter
Show More News
